High-Dose Allopurinol Reduces Left Ventricular Mass in Patients With Ischemic Heart Disease

被引:132
作者
Rekhraj, Sushma [1 ]
Gandy, Stephen J. [2 ]
Szwejkowski, Benjamin R. [1 ]
Nadir, M. Adnan [1 ]
Noman, Awsan [1 ]
Houston, J. Graeme [2 ]
Lang, Chim C. [1 ]
George, Jacob [1 ]
Struthers, Allan D. [1 ]
机构
[1] Univ Dundee, Ninewells Hosp & Med Sch, Div Cardiovasc & Diabet Med, Med Res Inst, Dundee DD1 9SY, Scotland
[2] Univ Dundee, Ninewells Hosp & Med Sch, Dept Clin Radiol, Dundee DD1 9SY, Scotland
基金
英国医学研究理事会;
关键词
allopurinol; ischemic heart disease; oxidative stress; ventricular hypertrophy; CHRONIC KIDNEY-DISEASE; CARDIOVASCULAR RISK; ENDOTHELIAL FUNCTION; OXIDATIVE STRESS; ANGINA-PECTORIS; URIC-ACID; HYPERTROPHY; HYPERTENSION; REGRESSION; DYSFUNCTION;
D O I
10.1016/j.jacc.2012.09.066
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives This study sought to ascertain if high-dose allopurinol regresses left ventricular mass (LVM) in patients with ischemic heart disease (IHD). Background LV hypertrophy (LVH) is common in patients with IHD including normotensive patients. Allopurinol, a xanthine oxidase inhibitor, has been shown to reduce LV afterload in IHD and may therefore also regress LVH. Methods A randomized, double-blind, placebo-controlled, parallel group study was conducted in 66 patients with IHD and LVH, comparing 600 mg/day allopurinol versus placebo therapy for 9 months. The primary outcome measure was change in LVM, assessed by cardiac magnetic resonance imaging (CMR). Secondary outcome measures were changes in LV volumes by CMR, changes in endothelial function by flow-mediated dilation (FMD), and arterial stiffness by applanation tonometry. Results Compared to placebo, allopurinol significantly reduced LVM (allopurinol -5.2 +/- 5.8 g vs. placebo -1.3 +/- 4.48 g; p = 0.007) and LVM index (LVMI) (allopurinol -2.2 +/- 2.78 g/m(2) vs. placebo -0.53 +/- 2.5 g/m(2); p = 0.023). The absolute mean difference between groups for change in LVM and LVMI was -3.89 g (95% confidence interval: -1.1 to -6.7) and -1.67 g/m(2) (95% confidence interval: -0.23 to -3.1), respectively. Allopurinol also reduced LV end-systolic volume (allopurinol -2.81 +/- 7.8 mls vs. placebo -1.3 +/- 7.22 mls; p = 0.047), improved FMD (allopurinol +0.82 +/- 1.8% vs. placebo -0.69 +/- 2.8%; p = 0.017) and augmentation index (allopurinol -2.8 +/- 5.1% vs. placebo +0.9 +/- 7%; p = 0.02). Conclusions High-dose allopurinol regresses LVH, reduces LV end-systolic volume, and improves endothelial function in patients with IHD and LVH. This raises the possibility that allopurinol might reduce future cardiovascular events and mortality in these patients. (Does a Drug Allopurinol Reduce Heart Muscle Mass and Improve Blood Vessel Function in Patients With Normal Blood Pressure and Stable Angina?; ISRCTN73579730) (J Am Coll Cardiol 2013; 61:926-32) (C) 2013 by the American College of Cardiology Foundation
引用
收藏
页码:926 / 932
页数:7
相关论文
共 27 条
[1]   The cardiovascular risk factor, left ventricular hypertrophy, is highly prevalent in stable, treated angina pectoris [J].
Ang, Donald Swee Cheng ;
Pringle, Stuart D. ;
Struthers, Allan D. .
AMERICAN JOURNAL OF HYPERTENSION, 2007, 20 (10) :1029-1035
[2]   Clinical Impact of Left Ventricular Hypertrophy and Implications for Regression [J].
Artham, Surya M. ;
Lavie, Carl J. ;
Milani, Richard V. ;
Patel, Dharmendrakumar A. ;
Verma, Anil ;
Ventura, Hector O. .
PROGRESS IN CARDIOVASCULAR DISEASES, 2009, 52 (02) :153-167
[3]   Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery - A report of the International Brachial Artery Reactivity Task Force [J].
Corretti, MC ;
Anderson, TJ ;
Benjamin, EJ ;
Celermajer, D ;
Charbonneau, F ;
Creager, MA ;
Deanfield, J ;
Drexler, H ;
Gerhard-Herman, M ;
Herrington, D ;
Vallance, P ;
Vita, J ;
Vogel, R .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2002, 39 (02) :257-265
[4]   Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol -: The Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) trial [J].
Devereux, RB ;
Dahlöf, B ;
Gerdts, E ;
Boman, K ;
Nieminen, MS ;
Papademetriou, V ;
Rokkedal, J ;
Harris, KE ;
Edelman, JM ;
Wachtell, K .
CIRCULATION, 2004, 110 (11) :1456-1462
[5]   Prognostic significance of left ventricular mass change during treatment of hypertension [J].
Devereux, RB ;
Wachtell, K ;
Gerdts, E ;
Boman, K ;
Nieminen, MS ;
Papademetriou, V ;
Rokkedal, J ;
Harris, K ;
Aurup, P ;
Dahlöf, B .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2004, 292 (19) :2350-2356
[6]   Allopurinol attenuates left ventricular remodeling and dysfunction after experimental myocardial infarction -: A new action for an old drug? [J].
Engberding, N ;
Spiekermann, S ;
Schaefer, A ;
Heineke, A ;
Wiencke, A ;
Müller, M ;
Fuchs, M ;
Hilfiker-Kleiner, D ;
Hornig, B ;
Drexler, H ;
Landmesser, U .
CIRCULATION, 2004, 110 (15) :2175-2179
[7]   High-dose allopurinol improves endothelial function by profoundly reducing vascular oxidative stress and not by lowering uric acid [J].
George, Jacob ;
Carr, Elaine ;
Davies, Justine ;
Belch, J. J. F. ;
Struthers, Allan .
CIRCULATION, 2006, 114 (23) :2508-2516
[8]   Effect of Allopurinol in Chronic Kidney Disease Progression and Cardiovascular Risk [J].
Goicoechea, Marian ;
Garcia de Vinuesa, Soledad ;
Verdalles, Ursula ;
Ruiz-Caro, Caridad ;
Ampuero, Jara ;
Rincon, Abraham ;
Arroyo, David ;
Luno, Jose .
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2010, 5 (08) :1388-1393
[9]   Left ventricular hypertrophy - the problem and possible solutions [J].
Gosse, P .
JOURNAL OF INTERNATIONAL MEDICAL RESEARCH, 2005, 33 :3A-11A
[10]   Comparison of interstudy reproducibility of cardiovascular magnetic resonance with two-dimensional echocardiography in normal subjects and in patients with heart failure or left ventricular hypertrophy [J].
Grothues, F ;
Smith, GC ;
Moon, JCC ;
Bellenger, NG ;
Collins, P ;
Klein, HU ;
Pennell, DJ .
AMERICAN JOURNAL OF CARDIOLOGY, 2002, 90 (01) :29-34